MRK is overvalued and will drop

Discussion in 'Stocks' started by hajimow, Jan 9, 2017.

  1. hajimow

    hajimow

    I shorted MRK by selling weekly Call 61 and 61.5. I rarely directly short the stock. But MRK going up 5% just by an approval of an application for a drug was a call for shorting.
     
    #11     Jan 11, 2017
  2. hajimow

    hajimow

    MRK imploding !!!
     
    #12     Jan 11, 2017
    vanzandt likes this.
  3. Jamie J.

    Jamie J.

    MRK looks awful. Get rid of it as soon as possible
     
    #13     Jan 11, 2017
  4. $ONCS interesting the big $MRK approval today was to use keytruda with chemo. They are looki g to expand the use of product...partnership?
     
    #14     Jan 12, 2017
  5. Jamie J.

    Jamie J.

    Do you think it will save the situation? I doubt it.
     
    #15     Jan 12, 2017
  6. Merck Is Best Performing DJIA Stock So Far in 2017
     
    #16     Jan 17, 2017
  7. hajimow

    hajimow

    Covered my short position today with a nice profit and increased my short position on MMM.
     
    #17     Jan 19, 2017
  8. hajimow

    hajimow

    MRK is again in short territory. Shorted on Thursday. Will drop to $60 in less than a week.
     
    #18     Feb 3, 2017
  9. ironchef

    ironchef

    No offense, but I still remember you told all of us to short MCD and that it won't be around in 5 years while all that time you kept selling puts on MCD, a bullish bet. Just a reminder, MCD is @ $124 today (~$85 then).

    As for MRK, I won't short it because of one word: Keytruda.

    Cheers.
     
    #19     Feb 3, 2017
  10. dealmaker

    dealmaker

    FDA OKs Merck's Keytruda to treat cancers with genetic defects
    Food and Drug Administration on Tuesday approved Merck & Co.'s Keytruda drug to treat tumors with a certain genetic defect -- the first time the agency has cleared a cancer drug for a use not tied to the site of a tumor. The FDA approved Keytruda to treat tumors with genetic defects known as "microsatellite instability" or "mismatch repair" deficiencies, which are present in an estimated 4 percent of cancers. (Morningstar)
     
    #20     May 24, 2017